HomePress ReleaseEpilepsy Drugs Market, Size, Global Research 2024-2030 Featuring Eisai, UCB, H. Lundbeck,...

Epilepsy Drugs Market, Size, Global Research 2024-2030 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott Laboratories, Alkem Laboratories, Bausch, GSK, Novartis, and Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis” report has been added to ResearchAndMarkets.com’s offering.

The Global epilepsy drugs market is expected to approach approximately US$ 10.28 billion by 2030 from US$ 7.62 Billion in 2023. Between 2024 and 2030, the global epilepsy drugs market is predicted to develop at a compound annual growth rate (CAGR) of 4.37%.

The persistent demand for these medicines is driven by the necessity to correctly manipulate and control seizures. Additionally, ongoing advancements in drug improvement and remedy techniques always enlarge the options available to sufferers and healthcare companies. This popularity underscores the essential role of epilepsy drugs in enhancing patient outcomes and enhancing the satisfaction of lifestyles for those affected by epilepsy.

The World Health Organization (WHO) states that epilepsy ranks among the most common neurological conditions worldwide, impacting an estimated 50 million individuals. The marketplace is witnessing a boom propelled by the advent of recent and stepped forward medicinal drugs, offering additional remedy alternatives. Addressing the evolving wishes of individuals with epilepsy through advanced pharmaceutical interventions will become essential, given the interplay of these factors.

Further, innovative drug formulations like extended-release drugs and novel drug delivery methods are improving the variety of treatment options available for epilepsy patients. These new improvements in drug delivery technology assist in addressing demanding situations like dosing frequency and fluctuating blood levels, ultimately leading to higher patient effects. Matching treatment techniques to precise epilepsy kinds and individual patient necessities increases the need for a wide range of medications, supporting the development of the global epilepsy drugs market. The market strives to satisfy the evolving needs of patients worldwide by providing numerous medicine options to enhance patient compliance and treatment efficacy.

RELATED:  The Cannabist Company and Bloom Introduce Cutting Edge Vape Brand to New East Coast Markets

Also, the significant market percentage for epilepsy drugs may be in North America. This is because of a boom in neurological problems like Parkinson’s ailment, along with multiplied focus and tremendous research outcomes. The US invests in growing new epilepsy drugs, enhancing the general marketplace.

The United States is projected to experience a substantial increase in the market for epilepsy drugs. This is because of the increasing burden of epilepsy and the market players’ strategic projects, focus campaigns, and the launch of the latest products. According to a press release of the CDC in 2022, around 3.4 million Americans have epilepsy, and about 1 in 10 people may additionally experience a seizure throughout their lifetime. The United States has over 260 epilepsy centers, wherein healthcare vendors concentrate on dealing with epilepsy and offering professional care to kids and adults. As a result, the prevalence of epilepsy within the area is predicted to force the demand for its remedy, leading to an expanded market increase.

According to the Parkinson’s Foundation, 930,000 humans within the US have Parkinson’s ailment, and this is anticipated to develop to 1.2 million by 2030. The Asia-Pacific region is also increasing and is estimated to have the fastest expansion because of the large population there. Epilepsy is a significant healthcare challenge in that place because of the wide variety of people affected by it.

The epilepsy drugs market has a significant share of the second-generation drug category

By drug category, the global epilepsy drugs market is fragmented into First Generation Drugs, Second Generation Drugs, and Third Generation Drugs. The phase of second-generation medicinal drugs held a sizeable portion of the epilepsy drugs market, largely because of their focused method of addressing various sorts of seizures with decreased side effects.

Additionally, they offer broader applicability and a lower danger of drug interactions. Referred to as more modern AEDs (antiepileptic drugs), second-generation medicines constitute an extra modern-day class of antiepileptic treatments developed through researchers to improve efficacy, tolerability, and protection compared to their predecessors. Examples consist of levetiracetam, lamotrigine, and topiramate.

RELATED:  Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year

Focal seizures command a prominent share in the global epilepsy drugs market

By seizure types, the global epilepsy drugs market is segmented into Focal Seizures, Generalized Seizures, and Non-Epileptic Seizures. Focal seizures are anticipated to be among the most remarkable portions of the global epilepsy drugs market. This is because of their vast occurrence and diverse manifestations.

As one of the most common seizure types, focal seizures affect a massive number of epilepsy sufferers across the world. Their numerous presentations, from subtle to severe, necessitate diverse remedy alternatives, pivoting the call for pharmaceutical interventions. Companies prioritize studies and development of drugs tailored to address the particular needs of individuals experiencing focal seizures, solidifying their prominence inside the epilepsy drugs market.

The drug stores and retail pharmacies segment had one of the highest shares in the global epilepsy drugs market

By distribution channels, the global epilepsy drugs market is categorized into hospital pharmacies, drug stores, retail pharmacies, and online providers. The drug stores and retail pharmacies section stands out as having one of the most substantial shares within the international epilepsy tablets market. This is driven by the extensive accessibility of these outlets, imparting convenient access to a wide variety of antiepileptic medicines.

Patients frequently rely upon these institutions for routine prescription refills and pharmacist consultations, contributing drastically to the section’s market percentage. Drug shops and retail pharmacies’ convenience, availability, and information solidify their pivotal function in distributing epilepsy drugs worldwide.

Exploring the Disease – Background and Key Insights

Classification of Epilepsies

  • West Syndrome
  • Dravet syndrome
  • Lennox-Gastaut syndrome
  • Landau-Kleffner syndrome
  • Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
  • CDKL5 deficiency disorder (CDD)
RELATED:  Cambria Launches Cambria Large Cap Shareholder Yield ETF


  • Antiepileptic Medications (AEDs)
  • Receptor Blockers
  • Others
  • Diet Therapy
  • Surgery
  • Phase I Evaluation (Noninvasive Tests)
  • Phase II Evaluation (Invasive Mon)
  • Treatment Algorithm for Medical Condition
  • Treatment Guidelines
  • American Epilepsy Society
  • American Family Physician – Epilepsy Treatment Options (2017)
  • The International League against Epilepsy (ILAE) Epilepsy Guidelines
  • NICE Guidelines: (2022)
  • Living and Coping with Epilepsy

Analysis of Marketed Medications/Drugs

  • EPIDIOLEX/EPIDYOLEX (cannabidiol) – Jazz Pharmaceuticals
  • XCOPRI/ONTOZRY(cenobamate) – SK Biopharmaceutical/ Pharma/Ono Pharmaceutical
  • FINTEPLA (fenfluramine) – UCB/Nippon Shinyaku
  • NAYZILAM (midazolam) nasal spray – UCB Pharma
  • VALTOCO (diazepam nasal spray) – Neurelis/Aculys Pharma
  • ZTALMY (ganaxolone) – Marinus Pharmaceuticals/Ovid Therapeutics/Orion
  • BRIVIACT/NUBRIVEO (brivaracetam) – UCB Pharma
  • FYCOMPA (perampanel) – Eisai/Catalyst Pharmaceutical
  • OXTELLAR XR (oxcarbazepine) – Supernus Pharmaceuticals
  • VIMPAT (lacosamide) – UCB Pharma/Daiichi Sankyo

Analysis of Emerging Drugs

  • XEN1101 – Xenon Pharmaceuticals
  • LIBERVANT (diazepam buccal film) – Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
  • Soticlestat (TAK-935) – Takeda/Ovid Therapeutics
  • COMFYDE (carisbamate) – SK Biopharmaceuticals (SK Life Science)
  • BHV-7000 (KB-3061) – Biohaven Pharmaceuticals/Knopp Biosciences
  • STACCATO alprazolam (benzodiazepine) – UCB Pharma/Alexza Pharmaceuticals
  • NBI-827104 (ACT-709478) – Neurocrine Biosciences/Idorsia Pharmaceuticals
  • Ivermectin (EQU-001) – Equilibre Biopharmaceuticals

Key Players Analysis

  • Eisai Co., Ltd.
  • UCB Inc.
  • H. Lundbeck A/S
  • GW Pharmaceuticals Plc.
  • Abbott Laboratories
  • Alkem Laboratories Limited
  • Bausch Health Companies Inc.
  • GSK plc
  • Novartis AG
  • Pfizer Inc

For more information about this report visit https://www.researchandmarkets.com/r/er5ix4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Keep exploring...

Related Articles

Luxury Cannabis Cigar Brand Launches Hand-Rolled Cannagar in New York Market

Colorado-Based Cannabis Brand, Made in Xiaolin, Expands Product Offerings to New York, Returns to...

NJOY Receives First FDA Authorizations for Menthol E-Vapor Products

RICHMOND, Va.--(BUSINESS WIRE)--$MO--Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food...

Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year

The fifth annual Report on Business editorial benchmark identifies top-level Canadian businesses with the...

One80 Intermediaries Offers Liability Insurance for Chief Restructuring Officers

The policy covers gaps between the distressed company’s insurance and that of their Chief...

Life Is Chill Expands Line of THC Soft Gels with New Live Resin THC Capsules, A First Of Its Kind for the Arizona Market

The new plant-based soft gel will launch on Friday, January 19, providing Arizona consumers...

Find Your YAY! with the Launch of YAY!’s All-Natural, Plant-Based Product Line to Transform Sexual Wellness and Self-Care

WINCHESTER, Ky.--(BUSINESS WIRE)--YAY!, the brand daring to redefine sexual wellness and holistic self-care, is...